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Neurodegenerative phenotypes reflect complex,
time-dependent molecular processes whose eluci-
dation may reveal neuronal class-specific therapeu-
tic targets. The current focus in neurodegeneration
has been on individual genes and pathways. In
contrast, we assembled a genome-wide regulatory
model (henceforth, ‘‘interactome’’), whose unbiased
interrogation revealed 23 candidate causal master
regulators of neurodegeneration in an in vitro model
of amyotrophic lateral sclerosis (ALS), characterized
by a loss of spinal motor neurons (MNs). Of these,
eight were confirmed as specific MN death drivers
in our model of familial ALS, including NF-kB, which
has long been considered a pro-survival factor.
Through an extensive array of molecular, pharma-
cological, and biochemical approaches, we have
confirmed that neuronal NF-kB drives the degenera-
tion of MNs in both familial and sporadic models of
ALS, thus providing proof of principle that regulatory
network analysis is a valuable tool for studying cell-
specific mechanisms of neurodegeneration.
INTRODUCTION
The contribution of non-neuronal cells such as astrocytes to the
demise of neighboring neurons in a variety of neurodegenerativedisorders (Garden and La Spada, 2012), including amyotrophic
lateral sclerosis (ALS), is increasingly recognized. Specifically,
we previously reported that astrocytes carrying a mutation in
the superoxide dismutase-1 (SOD1) gene, which accounts for
12% of familial ALS cases (Renton et al., 2014), selectively
kill mouse primary spinal motor neurons (MNs) and embryonic
stem cell-derived MNs (ES-MNs) (Nagai et al., 2007; Re et al.,
2014). This spontaneous neurodegenerative phenotype was
observed either when MNs were cultured in the presence of
mSOD1-expressing astrocytes or when they were exposed to
medium conditioned by mutant astrocytes (Nagai et al., 2007;
Re et al., 2014). Mirroring these findings frommouse, we showed
that astrocytes derived from postmortem CNS samples of
human sporadic ALS patients were also toxic to human ES-
MNs (Re et al., 2014). Furthermore, it has been reported that
mSOD1-expressing glial-restricted precursor cells grafted into
spinal cords of wild-type rats causeMN loss in living animals (Pa-
padeas et al., 2011) and that selective reduction ofmSOD1 levels
in astrocytes prolongs survival in SOD1G37R transgenicmice (Ya-
manaka et al., 2008). Taken together, these observations sug-
gest that astrocyte-triggered neurodegeneration is a general
phenomenon in ALS and is not restricted to in vitro systems,
mouse cells, or mSOD1-linked ALS.
Phenotypic changes effected by pathological events are now
routinely captured by gene expression profile (GEP) measure-
ments, determining mRNA abundance on a genome-wide scale
in a cellular population (Klein et al., 2003; Tothill et al., 2008). We
have shown that analysis of large GEP datasets, using algorithms
such as ARACNe, can produce accurate and comprehensive rep-
ertoires of regulatory interactions between transcription factorsCell Reports 12, 335–345, July 14, 2015 ª2015 The Authors 335
Figure 1. Purified ES-MNs Exposed to
mSOD1 ACM Is a Potent Model to Study
Non-Cell-Autonomous MN Degeneration
in ALS
(A) Immunocytochemical illustrations and pie
charts of cultures before and after MACS enrich-
ment. Scale bars, 20 mm.
(B) Immunocytochemical illustrations and bar
graphs of purified ES-MN numbers after 7 days
exposure to non-toxic (NTg ACM) or toxic mSOD1
ACM. Scale bars, 60 mm. *Student’s t test: t(8) =
3.78, p = 0.0054.
(C) Time course of purified ES-MN loss upon
exposure to ACM. ES-MNs are counted at the
indicated exposure days. Lower than mSOD1
ACM at day 1 and NTg ACM at all tested days (*p <
0.05, **p < 0.01; Newman-Keuls post hoc).
(D) At 2 days post-plating, purified ES-MNs are
exposed to ACM for 1, 2, 3, or 7 days, after which
medium is replaced with fresh medium and cells
are cultured for an additional 6, 5, 4, or 0 days,
respectively. ES-MN numbers are determined af-
ter 7 days exposure to ACM + fresh medium (FM).
Bars show the number of viable ES-MNs treated
with mSOD1 ACM relative to the ones treated with
NTg ACM (*p < 0.01; Newman-Keuls post hoc).
Data are shown asmean ± SEM; n = 5 each group.(TFs) and their transcriptional targets, known as regulatory net-
works or interactomes (Basso et al., 2005; Margolin et al., 2006).
Interactome interrogation using the MAster Regulator INference
algorithm (MARINa) has been especially effective in identifying
TFs that could be experimentally validated as causal master regu-
lators (MRs), i.e., genes that are both necessary and sufficient for
implementation of phenotypes (Aytes et al., 2014; Carro et al.,
2010; Lefebvre et al., 2010). However, such methods have never
been used to identify drivers of neurodegenerative phenotypes.
In this paper, we show that computational assembly and inter-
rogation of neural-tissue-specific interactomes using GEP sig-
natures derived from purified ES-MNs, following exposure to
mSOD1 astrocyte-conditioned medium (ACM) for 3 days, identi-
fied 23 TFs as candidate MRs (i.e., drivers) of neurodegeneration.
Of the 22 for which small hairpin RNA (shRNA)-mediated silencing
reagents were available, 14 (64%) were shown to modulate MN
loss. Specifically, silencing these genes inMNs decreased neuro-
degeneration, and of these, 11 displayed mSOD1 astrocyte-spe-
cific effects. Validated MRs included a key subunit of the nuclear
factor kappa B (NF-kB) complex, whose role as effector of
mSOD1 astrocyte-induced MN death was further confirmed by
genetic and pharmacological approaches. Taken together, these
data demonstrate the value of interactome analysis, using appro-
priate in vitro models, as an effectivemethodology to generate in-
sights into the mechanisms of neurodegeneration.
RESULTS
A Model of Non-Cell-Autonomous Neurodegeneration
in ALS
Our earlier studies (Nagai et al., 2007) required co-culturing MNs
with primary astrocytes or using mixed ES-MNs populations,336 Cell Reports 12, 335–345, July 14, 2015 ª2015 The Authorswhich prevented generation of MN-specific GEP signatures.
Thus, to generate signatures representative of early changes in
MNs, following exposure to toxic mSOD1-expressing astro-
cytes, we had to first develop an in vitro model system yielding
sufficiently homogeneous ES-MNs.
Accordingly, we started by substituting the glial cell monolayer
with ACM (Nagai et al., 2007), thus avoiding signature contami-
nation by co-cultured astrocytes. Then, to enrich ES-MN purity,
we tested two distinct purification methods: fluorescence-acti-
vated cell sorting (FACS) and magnetic-activated cell sorting
(MACS). For the latter, we used a murine ES Hb9::GFP reporter
cell line stably transduced with a viral vector expressing the
cell-surface receptor CD2 (cluster of differentiation 2), under
the control of the MN-specific promoter Hb9. Both FACS and
MACS purification processes gave 91% cell purity following
ES-MN differentiation. Yet, total yield of purified ES-MNs using
MACS was 5-fold greater than with FACS. MACS-purified
ES-MNs (Figure 1A) remained susceptible to mSOD1 ACM
exposure for 7 days (Figure 1B), thus eliminating the possibility
that such process might select for non-representative ES-MN
subpopulations or that CD2 expression might affect ES-MN
properties.
Next, to select the most relevant time points for GEP signature
generation, we studied the kinetics of purified ES-MN loss in
response to mSOD1 ACM. For up to 2 days, no difference could
be detected in the number of ES-MNs exposed to mSOD1 or to
non-transgenic (NTg) ACM (Figure 1C). Thereafter, the number of
ES-MNs exposed to mSOD1 ACM declined monotonically until
7 days, reaching 50% ± 4% (n = 5, mean ± SEM) of the value
in control cultures (Figure 1C). Between 7 and 14 days exposure,
therewas no further reduction in the number of ES-MNs exposed
to mSOD1 ACM as compared to those exposed to NTg ACM
AB
Figure 2. Enrichment of the Necroptosis Program in the mSOD1-
Induced GES
(A) Gene set enrichment analysis for 40 neuron-specific necroptosis genes on
the 1d-GES
(B) Same at 3d-GES.
Themaximum value of the curve determines the enrichment score. The vertical
lines indicate the projection of the neuron-specific necroptosis genes on the
sorted GES (indicated by the color scale in Z score units). The normalized
enrichment score (NES) and associated p value are shown on each plot.
See also Table S1.(Figure 1C). The kinetics and magnitude of ES-MN loss were
comparable to those reported for mouse primary spinal MNs
(Nagai et al., 2007) and for human ES-MNs exposed to sporadic
human astrocytes (Re et al., 2014).
Finally, we assumed that activity of MN death drivers would
likely occur before ES-MNs become irreversibly committed to
death. To test for the existence of such a ‘‘point of no return,’’
ES-MNs were exposed to mSOD1 ACM for varying times, prior
to switching to fresh MN medium, for a combined time of
7 days (Figure 1D). Exposure to mSOD1 ACM for %2 days did
not induce MN loss compared to controls (Figure 1D). In
contrast, exposure to mSOD1 ACM for R3 days was sufficientto trigger loss of 50% of MNs at 7 days (Figure 1D). Thus, sus-
ceptible ES-MNs become committed to death by 3 days expo-
sure to mSOD1 ACM. Taken together, these observations
suggest that purified ES-MNs exposed to mSOD1 ACM provide
a reliable non-cell-autonomous model of progressive neurode-
generation. Moreover, their expandable nature, relevance to
human disease, and synchronicity of death commitment by sus-
ceptibleMNsmake this a robust in vitromodel to explore themo-
lecular basis of neurodegeneration in ALS.
Gene Expression Signature of MN Death
To identify molecular events correlated with neurodegeneration,
we profiled gene expression by ES-MNs after 1 day and 3 days of
exposure to either mSOD1 ACM, NTg ACM, or culture medium
conditioned by astrocytes from transgenic mice overexpressing
wild-type SOD1 (wtSOD1 ACM). Like NTg ACM, the latter is not
toxic to ES-MNs (Nagai et al., 2007) but controls for any effects
SOD1 overexpression might have on the GEP signatures. After
correcting for potential GEP batch effects using a linear model
that accounts for both treatment and batch variance, we esti-
mated statistical significance by a moderated Student’s t test
(see Experimental Procedures). At 1 day following exposure,
there were only 79 differentially expressed genes (false discov-
ery rate [FDR] < 1%) between ES-MNs exposed to either
mSOD1 or control ACMs. However, at 3 days of exposure, there
were 620 differentially expressed genes (FDR < 1%; see Table
S1). All profiled genes were rank-sorted from the most under-
to the most overexpressed, based on the moderated t-statistic
(see Experimental Procedures), to produce a 3-day (3d) gene
expression signature (GES).
To support the relevance of the generated GESs to the death
mechanisms of MNs, we first performed a gene set enrichment
analysis between our data and a set of 40 neuron-specific nec-
roptosis-associated genes, previously characterized through a
loss-of-function screen in zVAD-fmk-treated mouse fibrosar-
comacells (Hitomi et al., 2008). This specific analysiswaspromp-
ted by our demonstration that both mouse mSOD1 familial-ALS
and human sporadic ALS astrocytes kill MNs by necroptosis
(Re et al., 2014), a caspase-independent form of programmed
cell death (Pasparakis and Vandenabeele, 2015). Strikingly, the
necroptosis-associated genes that were inferred to be ex-
pressed in normal neurons were highly enriched in the 3d-GES,
but not in the 1-dayGES (Figure 2; Table S1). These findings sug-
gest that the 3d-GES may be particularly suitable to dissect the
molecular drivers of MN death in our ALS models.
Regulatory Mechanisms Controlling MN Death in
Response to mSOD1 ACM
To identify the genes driving the 3d-GES, thus being the causal
determinants of MN degeneration, we utilized the previously
validated MARINa algorithm (Carro et al., 2010; Lefebvre et al.,
2010). A critical requirement for utilization of the algorithm is the
availability of a context-specific interactome, representing a
genome-wide map of regulatory interactions (i.e., the repertoire
of transcriptional targets that are activated or repressed by
each TF in the cellular context of interest). Assembly of such an
interactome using the ARACNe algorithm requires >100 GEPs
from independent samples, representative of a particular cellularCell Reports 12, 335–345, July 14, 2015 ª2015 The Authors 337
Figure 3. Optimal Interactome and InferredMaster Regulators of the
ES-MN Molecular Phenotype Induced by 3 Days of Exposure to
mSOD1 ACM
(A) Number of regulators (y axis) inferred as differentially active by MARINa for
the mSOD1 ACM treated ES-MN 3-day GES, using seven alternative inter-
actomes (indicated in the plot insert) for different false discovery rate (FDR)
levels (x axis). The plot insert shows the quantification of MARINa performance
on seven alternative interactomes (x axis) as the area under the curves shown
in (A). See the Supplemental Experimental Procedures for interactome details.
(B) Statistically significant MRs inferred by MARINa analysis of the BrainNet,
using the 3-day signature of MNs exposed to mSOD1 ACM. The x axis rep-
resents all genes, sorted from that with the largest decrease to the one with
the largest increase in expression. For each MR, activated and repressed
338 Cell Reports 12, 335–345, July 14, 2015 ª2015 The Authorscontext of interest (Margolin et al., 2006). Since aMN-specific in-
teractome is not currently available, we evaluated whether other
ARACNe-inferred interactomes (Basso et al., 2005), assembled
from lineage-related tissues, could be used instead (see the Sup-
plemental Experimental Procedures). To select an optimal inter-
actome, we first assessed whether statistical significance of
MARINa-inferred MRs may represent a good indication of the
interactome’s ability to represent a specific cellular context.
This was confirmed by both increasingly degrading interactomes
(in silico) and by using non-tissue-matched interactomes, which,
as expected, substantially reduced the statistical significance of
inferred MRs (Figure S1; Experimental Procedures). MARINa
analysis of the 3d-GES using seven distinct ARACNe-inferred
interactomes revealed that a murine whole-brain interactome
(BrainNet) outperformed all others, including those obtained
from human glioma, neuroblastoma, and prefrontal cortex, as
the most appropriate model for the murine ES-MN context (Fig-
ure 3A). The BrainNet was assembled by ARACNe analysis of
437mouse brain biopsy specimens, obtained fromseven distinct
brain regions of 20 inbred mouse strains, profiled by Nadler et al.
(GEO: GSE10415).
MARINa-based interrogation of the BrainNet using the 3d-GES
identified 23 candidate MRs (FDR < 1%) as potential drivers of
mSOD1 ACM-induced ES-MN death (Figure 3B; Table S2). As
we have observed in other systems, despite robust changes in
expression of downstream genes in response to the 3-day expo-
sure to ACM, only three of the candidate MRs (Atf5, Hmgb2 and
App) were differentially expressed between mSOD1 and control
ACM-treated ES-MNs (FDR < 1%), and none of them were in the
top 100most differentially expressed genes (ranking at positions
170, 368, and 584, respectively; Figure 3B).
Experimental Validation of MARINa-Inferred Master
Regulators
To validate these candidate MRs, we tested their role in astro-
cyte-induced MN death using lentiviral shRNA silencing in
primary embryonic MNs grown on mSOD1 or NTg astrocyte
monolayers (AML); Zfp235 could not be tested due to shRNA
unavailability. For each of the 22 tested genes, two distinct,
validated Mission shRNA hairpins were utilized. Thus, 44ARACNe-inferred targets are shown as red and blue bars, respectively, to
indicate that MARINa considers them separately to compute MR significance
(see Experimental Procedures for details. Due to the uncertainty in assigning
directionality to a MR (see text), all significant MRs are included, comprising
both those predicted as positive (Zdhhc2, Cbfa2t3, App, Zfp235, Hivep2,
Epas1, Camta1, Dennd4a, Smad3, and Mycn) and negative (Zfp646, Tgif1,
Hmgb2, Myb, Tcf7, Trp53, Zfp503, Atf5, Nfkb1, Psmc3ip, Tcf3, Zfp36l1, and
Irx5) MRs. To improve figure readability by showing a concordant enrichment
of activated and repressed targets, the x axis is inverted for MRs predicted to
be negative regulators of mSOD1 mediated toxicity. This transformation af-
fects only the display of the results, but not their analysis and interpretation. TF
names and FDR significance for differential MR activity, as computed by
MARINa, are shown to the right of the ‘‘bar-code’’ plot. The first and second
columns of the heatmap show a color code representative of differential TF
activity (absolute normalized enrichment score) and differential TF expression
(Z score), respectively. Numbers on the right of the heatmap represent the TF
rank among differentially expressed genes (e.g., Zdhhc2 is the 6,375th most
differentially expressed gene).
See also Figure S1 and Table S2.
AB
Figure 4. Candidate MR Validation
(A) ALS-related effect of shRNA-mediated TF silencing on surviving MNs. The
bars show the mean ± SEM for the ratio of the number of surviving ES-MN on
mSOD1 versus NTg AML following TF silencing, divided by the same ratio
when the cells were transduced with the control empty vector (EV).
(B) General viability effect of each TF silencing. The bars show themean ±SEM
for the ratio of the number of surviving ES-MNs following shRNA-mediated
silencing of a specific TF versus EV control, when cultured on an NTg astrocyte
monolayer. *FDR < 0.1, **FDR < 0.05, ***FDR < 0.01 (Student’s t test). Data are
shown as mean ± SEM; n = 3–4 each group. The bar colors indicate the
functional group of the driver gene, either ALS-related MN death driver (ALS-
related MNDD) or non-ALS-related death driver (Non-ALS-related MNDD).
See also Figure S2.shRNA-expressing viral vectors were individually used to infect
primary MNs in suspension, prior to seeding them on an astro-
cyte monolayer (AML). Each was confirmed to produce a
R60% reduction in targeted MR expression at 2 days post-
transduction, as assessed by qRT-PCR (Figure S2A). Primary
MNs were transduced with the validated shRNAs, plated on
either mSOD1 or NTg AML, and counted after 7 days (Fig-
ure S2C). To reduce the risk of changes due to off-target effects,
only consistent results reproduced by two distinct shRNA hair-
pins were considered. We first analyzed the degree to which
MR silencing improved the ratio of the number of MNs grown
on mSOD1 AML divided by the number of MNs grown on NTg
AML. Once normalized for minor changes induced by empty
vector control (Figure S2C), we found that silencing 11 of the
22 MRs increased the mSOD1 AML:NTg AML MN ratio (Fig-
ure 4A; yellow bars, FDR < 0.1, one-tailed Student’s t test);
hence, we termed these 11 genes ‘‘ALS-related MN death
drivers.’’ Of these, only eight (Tgif1, Nfkb1, Epas1, Psmc3ip,
Tcf7, Tcf3, Zfp36l1, and Zdhhc2) appeared as mSOD1 astro-
cyte-specific MN death drivers, since their silencing increased
the MN ratio without altering the number of MN grown on NTgAML (Figure 4B; yellow bars without asterisks), while the
silencing of the three remaining (Hmgb2, Hivep2, and Irx5)
increased both the ratio and the number of MNs grown on NTg
AML (Figure 4B; yellow bars with asterisks).
Furthermore, the silencing of three additional genes (Cbfa2t3,
Dennd4a, and Smad3) improved the number of MNs grown on
NTg AML but did not alter the mSOD1 AML:NTg AML MN ratio.
As such, these were classified as ‘‘non-ALS-related MN death
drivers’’ (Figure 4B, pink bars).
Notably, 8 of 22 genes (36%) were validated as mSOD1 astro-
cyte-specific MN death drivers, which represents a proportion
much higher than the one expected by chance (p = 4.4 3
1013, binomial test), assuming a true positive rate (TPR) < 1%
as reported in screens for genes affecting viability in a muta-
tion-specific manner (Beronja et al., 2013; Rosenbluh et al.,
2012). Overall, 14 of 22 candidate MRs (64%) were validated
as MN death drivers irrespective of the astrocyte genotypes,
which is also highly significant (p = 8.6 3 1011), assuming a
TPR% 10%, as previously observed for non-specific viability as-
says (Beronja et al., 2013).
NF-kB Is Activated in Response to mSOD1 ACM and
Mediates ES-MN Cell Death
Among the14validatedMNdeathdrivers, silencingofNF-kBsub-
unit encoded by the Nfkb1 gene, as evidenced byR75% reduc-
tion of both the mRNA and protein levels (Figures S2A and S2B),
was associated with the most statistically significant reduction
in mSOD1 AML-induced MN loss (Figure 4A), without any effect
on the number of MNs exposed to NTg astrocytes (Figure 4B).
Although increased expression of NF-kB subunit p65 in spinal
MNs from patients with ALS has been reported (Jiang et al.,
2005) and NF-kB activation in microglia has been linked to MN
degeneration in ALS models (Frakes et al., 2014; Swarup et al.,
2011), its role as a causal driver ofMN death remains to be estab-
lished. Thus, to provide additional validation of our unbiased
approach as a methodology for the identification of causal func-
tional determinants of MN neurodegeneration, we decided to
further investigate the role of NF-kB in MN death.
NF-kB is a heterodimeric protein complex composed of
different subunits of the Rel TF family, which upon activation,
translocates from the cytosol to the nucleus, where it binds to
the kB motif of target genes to regulate their expression (Ghosh
et al., 2012). Thus, to confirm NF-kB activation and to identify
the subunits involved, we performed a NF-kB DNA-binding
ELISA. This assay revealed a strong but transient increase in
DNA binding for the p50 and p65 subunits in nuclear extracts
of purified ES-MNs exposed to mSOD1 ACM (Figure 5A).
Conversely, no change in DNA binding was observed for NF-kB
subunits p52 and RelB (Figure S3A). Given the robust ELISA re-
sults obtained for the p65 subunit (Figure 5A), we also examined
its subcellular partition by western blot as an additional sign of
NF-kB canonical pathway activation in our ALSmodel. We found
that the nuclear, but not the cytosolic, content of p65 was
increased inMNs exposed tomSOD1, but not NTg ACM (Figures
5B and S3B). In light of these results, we returned to our 3d-GES
data (Table S1) and found that none of the NF-kB subunits were
differentially expressed at the mRNA level but that p50 and p65
encoded by Nfkb1 and RelA were significantly dysregulated atCell Reports 12, 335–345, July 14, 2015 ª2015 The Authors 339
Figure 5. NF-kBPathway Is Activated in ES-
MNs Exposed to mSOD1 ACM
(A) DNA-binding ELISA assay for the canonical
NF-kB pathway subunits p65 and p50 in nuclear
extracts from purified ES-MNs exposed to either
mSOD1 ACMor NTg ACM for 0 (just before adding
the ACM) to 7 days. The optical density (OD)
values are normalized to the OD of ES-MNs
exposed to NTg ACM for 0 days. *p < 0.05, **p <
0.01, ***p < 0.001 (Newman-Keuls post hoc test).
Data are shown asmean ± SEM; n = 3 each group.
(B) Western blot analysis for NF-kB p65 subunit
content in the nuclear fractions from purified ES-
MNs exposed for 1 to 4 days to either mSOD1 or
NTg ACM. Histone H3 is used as a nuclear
housekeeping marker. NF-kB control (Ctrl) is a cell
extract provided by Cell Signaling.
(C) Western blot analysis of phosphorylated IkB
(p-IkB) and total IkB from purified ES-MNs
exposed to either mSOD1 or NTg ACM for 1, 2, 3,
or 7 days. b-Actin is the loading control. p-IkB
protein content is normalized by the correspond-
ing amount of total IkB.
See also Figure S3.the protein activity level (FDR < 0.05) in MNs exposed to mSOD1
versus NTg ACM, as inferred by the MARINa analysis (Table S2).
Thus, collectively, these results support the notion that mSOD1
astrocyte-induced MN toxicity is associated with NF-kB activa-
tion via its canonical (p65-p50 complex) rather than non-canoni-
cal (p52-RelB complex) pathway. Critically, such a molecular
event was successfully detected by the interactome-based unbi-
ased approach.
Signals that induce NF-kB activity trigger the inactivation, by
phosphorylation, of its endogenous inhibitor, IkB (Ghosh et al.,
2012), and we observed an increase in cytosolic phosphorylated
IkB in MNs exposed to mSOD1 ACM that paralleled the nuclear
accumulation of p65 (Figures 5C and 5B). Given this finding, we
next decided to assess the effect of NF-kB inhibition on ACM-
induced MN death by using wedelolactone, a natural compound
that prevents the phosphorylation and ensuing degradation of
IkB (Kobori et al., 2004). Consistent with its known mechanism
of action, wedelolactone stabilized IkB in cultured MNs (Fig-
ure S4A) and protected against ES-MN loss caused by
mSOD1 ACM (Figure 6A). This effect was specific to NF-kB-
mediated cell death, since when we exposed primary MNs to
two other stressors known to kill MNs via non-NF-kB mecha-
nisms, Fas ligand (Raoul et al., 2002) and domoic acid (Xu
et al., 2008), wedelolactone conferred noprotection (Figure S4B).
These results were corroborated by a different NF-kB antago-
nist, namely BMS-345541, which also fully protectedMNdemise
in response to mSOD1 astrocytes (Figure S4C).
Because small molecules like wedelolactone or BMS-345541
are often fraught with off-target effects, we also assessed the
role of NF-kB in mSOD1-mediated MN loss by genetic means
using an adenoviral vector (AV) expressing a dominant-negative
IkB mutant. Consistent with the expected inhibition of NF-kB by
the IkB mutant, we observed increased levels of IkB directly
associated with the MOI used to transduce ES-MNs (Fig-
ure S4D), a consequent decrease in nuclear p65 and p50 (Fig-340 Cell Reports 12, 335–345, July 14, 2015 ª2015 The Authorsure 6B), and decreased levels of phosphorylated p65 (Figure 6C).
More importantly, ES-MNs transduced with MOI R 50 not only
showed near complete absence of p65 phosphorylation (Fig-
ure 6C) but also were resistant to mSOD1 ACM-induced toxicity
(Figure 6D).
Lastly, we targeted NF-kB in our fully humanized co-culture
model composed of astrocytes from adult human sporadic
ALS cases and human embryonic stem cell-derived MNs (Re
et al., 2014). As in the mouse mSOD1 model, wedelolactone
reduced the death of human ES-MNs exposed to human spo-
radic ALS astrocytes in a dose-dependent manner (Figure 6E).
Thus, upon exposure to familial or sporadic ALS astrocytes,
neuronal NF-kB, in contrast to its roles in many other settings
and cell types, is instrumental in driving MN death.
DISCUSSION
Interrogation of cell-context-specific interactomes assembled
de novo from large molecular profiles allows the identification
of key genetic modules and causal MRs underlying physiological
and pathological phenotypes (Aytes et al., 2014; Carro et al.,
2010; Lefebvre et al., 2010), as well as of causal driver mutations
responsible for the aberrant activity of these regulators (Chen
et al., 2014). However, interactome analysis for neurobiological
phenotypes remains poorly developed, with only a handful of
relevant examples. For instance, integrative analysis of a co-
expression network using both gene expression and GWAS
data was used to rank-order genes that may play a role in late-
onset Alzheimer’s disease (Zhang et al., 2013) and to elucidate
networks that may play roles in autism and schizophrenia (Chang
et al., 2015; Gilman et al., 2012). Despite these examples, we are
not aware of attempts made to interrogate causal interactomes
as a way of systematically elucidating and experimentally vali-
dating MRs of neurological disease. This is particularly vital in
adult-onset neurodegenerative disorders, where identification
Figure 6. Inhibition of NF-kB Activity Res-
cues ES-MNs Exposed to mSOD1 ACM
(A) At 2 day post-plating, purified ES-MNs ex-
posed to either mSOD1 or NTg ACM are treated
with wedelolactone at concentrations ranging
from 0.05 to 5 mM. After 7 days, the MNs are
fixed and their survival is assessed by immuno-
staining. *p < 0.05, **p < 0.01; Newman-Keuls
post hoc.
(B) Western blot analysis of IkB-a protein levels
in the cytoplasmic fractions, and NF-kB subunits
p50 and p65 in the nuclear fractions, from ES-MNs
transduced with adenoviral vectors carrying GFP
or super repressive IkB (IkB-SR) coding se-
quences (MOI 50). NF-kB translocation to the
nucleus was induced by TNF-a (10 ng ml1).
(C) Western blot illustrating the effect of adeno-
viral-mediated expression of super repressive IkB
(IkBSR) on phosphorylated p65 subunit (p-NF-kB)
in extracts frompurified ES-MNs exposed to either
mSOD1 or NTg ACM for 1 day in comparison to
ES-MNs transduced with adenovirus expressing
GFP only. b-Actin is the loading control.
(D) Effect of ES-MNs transduction by IkBSR
(50 MOI) against mSOD1 ACM ES-MN toxicity.
**p < 0.01 (Newman-Keuls post hoc test).
(E) Dose-dependent protection of wedelolactone
of human ES-MNs exposed to AML sporadic
ALS or non-disease control astrocytes. *p < 0.05,
**p < 0.01 (Newman-Keuls post hoc test).
Data are shown as mean ± SEM; n = 3–5 each
group. See also Figure S4.of potential therapeutic targets is strongly dependent on estab-
lishing more direct clues about the specific mechanism of
neuronal demise.
In the present paper, we report an unbiased, systems biology
analysis of GESs froman in vitro ALSmodel, using an interactome
that hadbeen reverse-engineered frommousewhole-brainGEPs.
Theproposed interactome-basedanalysiswassuccessful in iden-
tifying acomprehensiveset of regulatory genesdrivingMNdegen-
eration in a highly relevant cell model of ALS, including 14 causal
effector genes as well as their transcriptional programs. We
were able to experimentally confirm these inferences by showing
that lentiviral-mediated shRNA silencing of 11 of theseMRs in spi-
nal MNs reduced mSOD1 astrocyte toxicity. Of the 23 candidate
MRs predicted to regulate MN transcriptional response following
mSOD1 ACM exposure, only three were significantly differentially
expressed and none were among the top 100 most differentially
expressed. This finding is consistent with previous reports (Carro
et al., 2010; Lefebvre et al., 2010) and the fact that changes in MR
activity are likely post-translationally driven. Therefore, the pro-
posed methodology represents a significant progress over more
conventional GEP analyses, as it reliably and systematically iden-
tified causal functional determinants of the degenerative pheno-
type that were not differentially expressed.
Among the MRs whose silencing mitigated the MN death
phenotypes, eight (Tgif1, Nfkb1, Epas1, Psmc3ip, Tcf7, Tcf3,Zfp36l1, and Zdhhc2) reduced neuronal death following expo-
sure to mSOD1 astrocytes, without significantly altering the
number of surviving MNs following exposure to NTg astrocytes
(Figure 4). This phenotypic pattern is consistent with their spe-
cific role as key effectors of the lethal programs responsible for
killing MNs in response to mSOD1 astrocytes. Each of these
MRs has been linked to regulation of cell survival/death, espe-
cially during development, and, according to the Allen Spinal
Cord Atlas, they are all expressed in the spinal cord of the
mouse. However, except for NF-kB (Mattson and Camandola,
2001), none of these MRs have so far been associated with
adult-onset chronic neurodegenerative disorders. It will thus be
exciting to link the developmental role of theseMRs to their func-
tion in neurodegeneration.
Although, in most instances, NF-kB activation is known for
its pro-survival role, several lines of evidence suggest a patho-
genic role of this TF in ALS (Akizuki et al., 2013; Jiang et al.,
2005; Maruyama et al., 2010; Swarup et al., 2011). Yet, NF-kB
inactivation in MNs is not known to abrogate mSOD1 astro-
cyte-mediated MN death. Furthermore, among all of the other
identified MRs, we realized that high-quality reagents were
available for the study of NF-kB. Thus, NF-kB provided
the most direct and concrete proof of principle that our unbi-
ased approach can elucidate potentially meaningful neurode-
generative determinants. Accordingly, we performed a seriesCell Reports 12, 335–345, July 14, 2015 ª2015 The Authors 341
of in-depth functional studies on NF-kB in our in vitro models
of ALS. These investigations revealed that NF-kB canonical
pathway was activated in MNs exposed to mSOD1 ACM and
that its inhibition protects these neurons against mouse
mSOD1-expressing and human sporadic ALS astrocytes. Our
results thus confirm that NF-kB is a driver of MN death and
that this action is conserved between mouse and human and
shared between familial and sporadic ALS models. Our findings
also imply that MN death is mediated by NF-kB activation within
MNs and not glial cells, since astrocyte-specific NF-kB inhibition
does not attenuate MN death in transgenic mSOD1 mice (Crosio
et al., 2011) and our in vitro ALS models are essentially devoid of
microglia (Nagai et al., 2007; Re et al., 2014), which were shown
to kill cultured MNs by conventional NF-kB-dependent neuroin-
flammation (Frakes et al., 2014).
Our demonstration that inferred neuron-specific necroptosis
genes (Hitomi et al., 2008) are enriched in the 3d-GESmay be re-
garded as an independent confirmation of our recent report that,
in both mouse and human in vitro models of ALS, MNs die by
necroptosis (Re et al., 2014). However, we noted two intriguing
facts with respect to our findings and necroptosis. First, MN
degeneration is driven by activation and not repression of
NF-kB, as reported in other necroptosis contexts (Pasparakis
and Vandenabeele, 2015). For instance, in response to inflam-
matory stimuli in other cell types, NF-kB activation is promoted
by polyubiquitination of receptor-interacting protein-1 (RIP1)
whereas necroptosis is triggered by RIP1 deubiquitination and
phosphorylation (Pasparakis and Vandenabeele, 2015), two pro-
cesses that would appearmutually exclusive. Furthermore, it has
been reported that NF-kB can upregulate c-FLIPL, a caspase-
like molecule that forms a heterodimer with caspase-8 and
FADD (Micheau et al., 2001), and that the c-FLIPL-caspase-8-
FADD complex inhibits RIP3 activation and, consequently, nec-
roptosis (Dillon et al., 2012). A possible explanation to this
paradox may lie in the timing of the two events: upon mSOD1
ACM exposure, p65 and p50 DNA binding peak at 1 day (Fig-
ure 5A), whereas overt MN death occurs later (Figure 1C), sug-
gesting that NF-kB activation precedes rater then coincides
with the induction of necroptosis. Second, none of the neuron-
specific necroptosis genes found to be enriched in the 3d-GES
were identified as MRs of MN death (Figure 3). This may stem
from the fact that our analysis was restricted to genes annotated
as transcriptional regulators. Indeed, of the 40 inferred neuron-
specific necroptosis genes (Hitomi et al., 2008), only three are
represented as transcriptional regulators in our interactome
(Zfp521, Zmym3, and Sall2) and could have thus been inferred
by our analysis. Since these genes were identified by a small
interfering RNA screen of zVAD-fmk-exposed fibrosarcoma cells
followed by neuron gene-expression based filtering, and not
fromACM-exposedMNs, the probability that none of these three
genes is aMN-specific regulator of necroptosis is quite large (p =
0.38, based on a 27.5%overlap of the 40 gene signaturewithMR
targets). As a result, while the full signature may be enriched in
bona fide neuronal necroptosis regulators, there is no statisti-
cally significant expectation that any of these three genes may
regulate necroptosis in MNs. However, although none of these
genes were identified as MRs of MN death (Figure 3), the targets
(i.e., regulons) of four of the 11 validated MRs showed statisti-342 Cell Reports 12, 335–345, July 14, 2015 ª2015 The Authorscally significant overlap with the 40 inferred neuron-necroptosis
genes (Epas1, Hivep2, Tgif1, and Tcf7; FDR < 0.1, Fisher’s exact
test), suggesting a potential role of these MRs as drivers of nec-
roptosis in MNs. Clearly, future studies designed to assess the
necroptosis regulatory network, specifically in MNs, are war-
ranted to link ALS astrocyte-induced MN toxicity to this partic-
ular form of programmed cell death. Nonetheless, the current
knowledge of necroptosis signaling (Pasparakis and Vandena-
beele, 2015), taken together with the data demonstrating the
mutual involvement of RIP1 and NF-kB in our ALS models, sug-
gests that a member of the tumor necrosis receptor superfamily
(Tnfrsf) most likely transduces the astrocyte-mediated, extracel-
lular toxic signal. Given that Tnfrsf 1, 6, and 16 have previously
been excluded (Nagai et al., 2007; Re et al., 2014) and transcripts
for Tnfrsf 4, 8, 9, 11, 13, 14, 17, and 25 were not detected in our
ES-MNs (data not shown), this list can be narrowed considerably
to only a handful of potential candidates, whose role in engaging
necroptosis in MNs deserves further investigation.
In conclusion, early diagnosis and evaluation of efficacy in clin-
ical trials for all neurodegenerative disorders are hindered by the
absence of robust biomarkers for the first phase of the disease.
In addition, there is a chronic lack of validated therapeutic tar-
gets to allow for pharmacological intervention at early stages
of disease. Systems biology analysis of a cell culture system
that models non-cell-autonomous elements of neurodegenera-
tion allowed us to identify a statistically significant and numeri-
cally limited set of potential MRs of MN degeneration. These
drivers, including NF-kB, for which we provide proof-of-principle
validation, may in the future serve both as biomarkers and as
therapeutic targets for ALS. Furthermore, an extension of our
approach holds the promise of shedding comparable light on
the regulatory networks that are affected in other neurodegener-
ative diseases, which constitute a major challenge to society
over the coming decades. Indeed, regardless of whether these
genes will be confirmed as key effectors of human ALS pheno-
type, these results show that MR analysis is extremely effective
in identifying driver genes responsible for the implementation of
neurodegenerative phenotypes. In a field where discovery of key
mediators of disease phenotype has proven both complex and
inefficient, the ability to elucidate and validate more than a dozen
causal modulators of a death phenotype suggests that this kind
of analyses may significantly complement more traditional as-
says for the study of individual genes. Thus, further availability
of the human-derived ALS signature will allow us to either
confirm the identity of the currently reported genes or discover
their human counterpart.EXPERIMENTAL PROCEDURES
All human and animal studies were performed using protocols approved by,
respectively, the Institutional Review Board and the Institutional Animal Care
and Use Committee of Columbia University Medical Center.
Primary Cultures of Astrocytes and Preparation of ACMs
ACMs were prepared from astrocyte cultures of different genotypes,
collected, and frozen in several aliquots as described before (Nagai et al.,
2007; Re et al., 2014). On the day of the assay, ACM was supplemented
with 4.5 mg ml1 D-glucose (final concentration), 100 U ml1 penicillin, and
100 mg ml1 streptomycin (penicillin/streptomycin; Invitrogen) and trophic
factors (10 ng ml1 glial cell line-derived neurotrophic factor, 10 ng ml1 brain-
derived neurotrophic factor, and 10 ng ml1 ciliary neurotrophic factor [trophic
factor cocktail; R&D Systems]). The ACM was then filtered (0.22-mm cellulose
acetate membrane filter; Nalgene) before being added to the MN cultures.
Primary Culture of Human Astrocytes
Human astrocyte cultures were made following the protocol previously
described (Re et al., 2014) using fresh human autopsied tissues obtained
within 11 hr of death from Columbia Medical Center Morgue and the National
Disease Research Interchange (NDRI). Produced astrocytes were frozen in
Recovery Cell Culture Freezing Medium (Invitrogen) and stored in liquid nitro-
gen until used. All of the human astrocytes used in this study were passaged
for a maximum of five times.
Production of Primary MN Cultures
Spinal neuronal cultures were performed from embryonic day 12.5 Hlxb9-
GFP1Tmj transgenic rodents as previously described (Nagai et al., 2007).
The culture medium was either ACM or MN medium (neurobasal medium; In-
vitrogen) containing 2% horse serum (heat inactivated; Invitrogen), 2% B27
supplement, 0.5 mM glutamine (Invitrogen), 25 mM 2-mercaptoethanol, and
penicillin/streptomycin supplemented with the cocktail of trophic factors
described above.
Production of ES-MN Cultures and Purification Methods
Both human and mouse ES-MNs were produced as previously described (Na-
gai et al., 2007; Re et al., 2014). For purification of the mouse ES-MNs (see
below), ESCs derived from transgenic Hlxb9-GFP1Tmj mice (Wichterle et al.,
2002) were engineered to express EGFP and CD2 driven by the mouse Hb9
promoter. The produced cell suspensions were washed with the MN medium
described above, resuspended (20 million cells ml1) in PBS containing 1%
BSA, and processed by FACS or MACS.
Cell sorting was performed using a Becton Dickinson FACS Aria cytometer
(BD Biosciences) at the Flow Cytometry Core Facility of Columbia University.
Forward scatter (FS) and side scatter (SSC) were collected through a filter. The
GFP signal was collected in the FL1 channel. A light-scatter gate was drawn in
the SSC versus FS plot to exclude debris and include the viable cells. Cells in
the gate were displayed in a single-parameter histogram for GFP and final gate
settings determined to collect the GFP+ cells. Post-sorting, the cells were
collected in MN medium supplemented with 3% fetal bovine serum. Before
plating, the purified MN suspensions were collected by centrifugation (300 3
g, 5 min) and resuspended in MN medium.
As for MACS, upon dissociation and wash with L15 medium (Sigma-Aldrich)
containing 50 mM EDTA, 4% BSA (Sigma), 25 mM glucose, 2% horse serum
(Sigma), 40 mgml1 DNase, 500 mgml1 insulin (Sigma-Aldrich), 0.01Mputres-
cine (Sigma-Aldrich), 10 mgml1 conalbumin (Sigma-Aldrich), and 30 mMNa2-
SeO3 (Sigma-Aldrich), cell suspensions were incubated for 20 min at 4
C in
80 ml L15 medium containing 2.1 mg anti-rat CD2 antibody (Invitrogen) per
15 million dissociated cells. After washing with L15 medium, cells were incu-
bated for 20 min at 4C with an anti-mouse antibody conjugated to magnetic
microbeads (Miltenyi Biotec). Finally, cells were passed through a magnetic
column to separate CD2-GFP+ cells from the other types. Post-sorting, the
cells were collected in MN medium and were plated for culture for 2 days in
MN medium before being exposed to ACM.
Immunocytochemistry
For immunocytochemistry, cells were processed as previously described (Na-
gai et al., 2007; Re et al., 2014). Primary antibodies used were rabbit polyclonal
anti-EGFP (1:1,000; Molecular Probes) and anti-HB9 (1:1,000; Abcam) and
mouse monoclonal anti-MAP2 (1:1,000; Chemicon).
GEP Analysis of ES-MNs
Total mRNA was isolated at 1 and 3 days (see the Supplemental Experimental
Procedures for details on strategies to reduce potential batch effects) using
TRI Reagent Solution (Ambion) and MagMAX-96 total RNA Isolation kit (Am-
bion). A minimum of 20 million, 100-nucleotide single-end reads were obtained
by a HiSeq2000 platform (Illumina), mapped to the mouse genome (UCSC-
mm9) with Bowtie (Langmead et al., 2009), and counted at the gene level usingGenomicFeatures R-system package (Bioconductor; Gentleman et al., 2004).
The expression data were then normalized to account for different library
sizes, and the variance was stabilized based on the negative binomial distribu-
tion as implemented in the DESeq R-system package (Bioconductor).
The raw and normalized data are available from the Gene Expression Omnibus
(GEO: GSE49023) and figshare (http://dx.doi.org/10.6084/m9.figshare.809573),
respectively. To account for batch effects, differential gene expression analysis
was performed by fitting a two-factor, linear mixed-effects model to the normal-
ized data, independently estimating the variance due to treatment and MN cul-
ture conditions (batch effect; see the Supplemental Experimental Procedures
for details). Statistical significance was estimated by a moderated Student’s t
test implemented in the limma package (Dudoit et al., 2003) for the R system
(Bioconductor).
Enrichment of the 1-GES and 3-GES on a set of 40 neuron-specific necrop-
tosis-associated genes (Hitomi et al., 2008) was performed by gene set enrich-
ment analysis as described in the original publication (Subramanian et al.,
2005).
Master Regulators Analysis
Interactomes were reverse engineered by ARACNe (Margolin et al., 2006) from
six different GEP data sets for 1,857 human and 1,507mouse transcription fac-
tors (see the Supplemental Experimental Procedures for details on the data-
sets and the algorithm). Human interactome genes were mapped to their
mouse orthologs by the HomoloGene database (http://www.ncbi.nlm.nih.
gov/homologene). All the interactomes used in this publication, as well as a
sweave file including the source code for the analysis workflow, are available
for download from figshare (http://dx.doi.org/10.6084/m9.figshare.809573).
We used an improved version of the MARINa original algorithm (Carro et al.,
2010; Lefebvre et al., 2010) with the following modifications: (1) it tests for a
global shift in the position of the regulons when projected on the GES instead
of the Kolmorogov-Smirnov test statistics; (2) it test the enrichment of each tail,
or globally, according to the regulator mode of action, either activator,
repressor or mixed, respectively; and (3) it takes into account pleiotropic regu-
lation of each target gene by multiple regulators when computing the enrich-
ment. Statistical significance, including p value and normalized enrichment
score (NES), is estimated by comparison to a null model generated by
permuting the samples uniformly at random 1,000 times. The MARINa algo-
rithm is implemented in the ‘‘ssmarina’’ R package available for download
from figshare (http://dx.doi.org/10.6084/m9.figshare.785718).
Gene Silencing in Primary MNs Using shRNA Lentiviral Particles
All lentiviral-particle-packaged shRNAs in pLKO.1-puro plasmids were ob-
tained from Sigma Mission (see the Supplemental Experimental Procedures).
As a control, Mission pLKO.1-puro Empty Vector Control Transduction Parti-
cles (#SHC001V; EV) were used in all of the experiments, since during our pilot
work, we found no difference between EV and Mission pLKO.1-puro Non-
Mammalian shRNA Control Transduction Particles, which target no known
mammalian genes (#SHC002V).
Freshly dissociated primary MNs were obtained as described above and
exposed to lentiviral particles at a MOI of 15. Then cells in suspension were
centrifuged (800 3 g, 30 min) before to be resuspended in fresh MN medium
and cultured for 7 days on mSOD1 AML. Thereafter, transduced cells were
fixed and counted following the protocols mentioned above. In each experi-
ment, some transduced MNs were also cultured without AML to verify the
efficiency of silencing following mRNA extraction. In addition, in each experi-
ment, non-transduced MNs were plated, in a separate 24-well plate, on NTg
versus mSOD1 AML to confirm the toxicity of mSOD1 AML on MNs.
Real-Time qRT-PCR
Confirmation of knockdown was performed by qRT-PCR using RNA samples
obtained from 24- or 96-well cell extraction (RNAqueous Micro-Kit, Ambion,
Invitrogen). RNA (50–100 ng) was first reverse transcribed to cDNA (500 ng
ml1) using Superscript II three-step reverse transcription PCR (Invitrogen). A
two-step qRT-PCR was carried out by Realplex 4 Mastercycler PCR System
(Eppendorf) using FAM-conjugated gene-specific primers (Applied Bio-
systems, Invitrogen) in triplicate for each sample. VIC-conjugated GAPDH
(Applied Biosystems), a standard and accepted housekeeping gene, wasCell Reports 12, 335–345, July 14, 2015 ª2015 The Authors 343
used as a control against which results were normalized. Melt-curve analysis
was done for all samples to exclude the possibility of primer-dimer formation.
Fold change was based on DDCT values (Applied Biosystems Guide to PCR).
Nuclear/Cytoplasmic Subcellular Fractionation
Harvested cells were homogenized in buffer A (250 mM sucrose, 20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 2 mM EDTA [pH 7.4]) supplemented
with a protease inhibitor cocktail (Complete mini, Roche Applied Science).
For each preparation, an aliquot of cell homogenate was saved and the rest
was centrifuged (15,000 rpm, 15 min). The pellet (P1) was used for nuclear
purification, whereas the supernatant (S1) was used for the cytosolic purifica-
tion. To purify nuclei, P1 was re-homogenized in buffer B (2 M sucrose, 50 mM
Tris-HCl, 5 mM MgCl2, 1 mM DTT, and 1 mM PMSF [pH 7.4]) supplemented
with the protease inhibitor cocktail and then centrifuged (15,000 rpm,
15 min) through a cushion of buffer B. The resulting pellet was enriched with
nuclei and was designated as nuclear fraction. As S1, it was centrifuged
(15,000 rpm, 15 min). The resulting supernatant was further centrifuged
(15,000 rpm, 15 min). The supernatant of the latter centrifugation was desig-
nated as the cytosolic fraction. After each preparation and prior to using, the
purities of the subcellular fractions were confirmed by western blot for subcel-
lular markers (histone H3 for nuclei and GAPDH for cytosol).
DNA-Binding Assay
To assess NF-kB activation, we quantified the DNA-bound NF-kB subunits
p50, p52, p65, and RelB using a commercial DNA-binding ELISA kit (TransAM,
Active Motif). For this assay, 20 mg of nuclear extracts, prepared as outlined
above, were added per well in a 96-well plate with 30 ml Complete Binding
Buffer provided with the kit and was run as recommended by the manufac-
turer. The colorimetric reaction was read with a spectrophotometer (Dtx 880
Multimode Detector, Beckman Coulter) at 450 nm.
Western Blots of Total and Phosphorylated Proteins
At the indicated selected time points after exposure to ACM or infection with
viral vector, MNs were harvested in lysis buffer containing sodium orthovana-
date and sodium fluoride to avoid dephosphorylation. The following primary
antibodies were used: rabbit anti-total NF-kB p65 antibody (Cell Signaling),
anti-phosphorylated NF-kB p65 antibody (Cell Signaling), anti-GAPDH anti-
body (Cell Signaling), anti-histone H3 (Cell Signaling), anti-total IkB (Cell
Signaling), anti-phosphorylated IkB (Cell Signaling), and mouse anti-b-actin
(Sigma-Aldrich). The dilution used for all the antibodies was 1:1,000, except
for b-actin, for which it was 1:20,000. Western blots using antibodies raised
against the cytosolic and nuclear markers cited above were used as loading
controls. All bands were quantified by Odyssey Infrared Imaging system using
IRDye dye-labeled secondary antibodies (LI-COR). Results were expressed as
ratios of arbitrary fluorescence units for the protein of interest over arbitrary
fluorescence units for loading controls or as ratios of phosphorylated protein
of interest over total protein of interest.
Pharmacological Treatments and AV Transduction
Wedelolactone (Calbiochem; final concentrations, 50 nM to 5 mM) or BMS-
345541 (Selleckchem.com; 5 mM) were dissolved in DMSO. TNF-a (Sigma-Al-
drich) was added to cultures at a concentration of 10 ng ml1 for either 20 min
or 1 hr. Fas ligand (Sigma-Aldrich) and domoic acid (Sigma-Aldrich) were
added to MNs at concentrations 10 ng ml1 (Raoul et al., 2002) and 1 mM
(Xu et al., 2008), respectively, after 5 days in vitro of being in fresh medium.
Cell survival was evaluated at 7 days in vitro by counting EGFP+ neurons as
described below. MNs were transduced with AV expressing either CMV-
GFP or CMV-IkB-SR (Aleyasin et al., 2004) with a MOI ranging from 25 to 100.
Statistics for Cell Counting and Western Blot
Each experiment was performed in two to three technical replicates, and data
are the average of three to five biological replicates. Results for the cell count-
ing were the average of three to six coverslips. Each coverslip was counted in
its entirety under fluorescent examination. All values are expressed as mean ±
SEM unless stated otherwise. Differences between means were analyzed us-
ing a two-tailed Student’s t test. Differences among means were analyzed us-
ing a two- or three-way ANOVA.When ANOVA showed significant differences,344 Cell Reports 12, 335–345, July 14, 2015 ª2015 The Authorspairwise comparisons between means were tested by Newman-Keuls post
hoc testing. In all analyses, the null hypothesis was rejected at the 0.05 level.
All statistical analyses were performed using SigmaStat (Systat Software) or R
(http://www.R-project.org/).
ACCESSION NUMBERS
The ES-MN RNA-seq expression data have been deposited to NCBI GEO and
are available under accession number GEO: GSE49023.
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